- Smog During Pregnancy Threatens Newborn Health
- Black Children Less Likely To Get Gene Tests for Neuro Disorders
- Adults Can Learn ‘Perfect Pitch,’ Study Suggests
- Juicing Diets Can Harm Health in Just 3 Days, Study Finds
- U.S. Gambling Addiction Searches Soar With Legal Sports Betting
- Can’t Find a Gastroenterologist? You’re Not Alone
- Flu and Stomach Bugs Are Spreading Fast—Are You Prepared?
- CDC Finds Undetected Bird Flu Infections in U.S. Dairy Veterinarians
- American Cancer Society Calls for Restoration of Key CDC, FDA Data
- States With Abortion Bans See More Infant Deaths
Rapivab Approved to Help Treat Flu

Rapivab (peramivir) has been approved by the U.S. Food and Drug Administration to treat influenza.
The intravenous drug inhibits an enzyme that releases viral particles from infected cells, the FDA explained Monday in a news release. Rapivab is approved for people 18 and older who have had flu symptoms for no more than two days.
Flu affects up to 20 percent of the American population each season, hospitalizing more than 200,000 people annually, the agency noted.
Rapivab’s safety and effectiveness were evaluated in a clinical study of almost 300 people with a confirmed case of the flu. Those given the newly approved drug had symptoms ease about 21 hours sooner than people who didn’t take the drug, the FDA said.
Common side effects included diarrhea and serious skin reactions. And the FDA stressed that Rapivab and other antiviral drugs are not substitutes for getting the annual flu vaccine.
Rapivab is produced by BioCryst Pharmaceuticals, based in Durham, N.C.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.